Adma Biologics Incorporated (NASDAQ:ADMA) Reports Decline in Sellers; Strong Momentum for Longs

October 12, 2017 - By Peter Erickson

 Adma Biologics Incorporated (NASDAQ:ADMA) Reports Decline in Sellers; Strong Momentum for Longs

Investors sentiment decreased to 0.56 in 2017 Q2. Its down 1.44, from 2 in 2017Q1. It is negative, as 2 investors sold ADMA Biologics Inc shares while 7 reduced holdings. 2 funds opened positions while 3 raised stakes. 7.48 million shares or 4.07% less from 7.79 million shares in 2017Q1 were reported.
Vanguard Gp holds 150,028 shares. Aisling Llc holds 2.29% in ADMA Biologics Inc (NASDAQ:ADMA) or 3.61 million shares. 348,870 were reported by Franklin Incorporated. Morgan Stanley holds 0% of its portfolio in ADMA Biologics Inc (NASDAQ:ADMA) for 8,237 shares. Moreover, Consonance Cap Management L P has 0.56% invested in ADMA Biologics Inc (NASDAQ:ADMA) for 1.27M shares. Geode Management Ltd Limited Liability Company accumulated 21,526 shares or 0% of the stock. 35,147 are held by Prelude Cap Management Limited Liability Corp. Moreover, Weiss Multi has 0% invested in ADMA Biologics Inc (NASDAQ:ADMA) for 20,000 shares. Spark Invest accumulated 10,700 shares. Perceptive Advisors Limited Liability Com accumulated 721,102 shares. 150,000 are held by Iguana Healthcare Management Limited Liability Company. Moreover, Fmr Limited Liability Com has 0% invested in ADMA Biologics Inc (NASDAQ:ADMA). Moreover, Blackrock Incorporated has 0% invested in ADMA Biologics Inc (NASDAQ:ADMA) for 16,856 shares. Tower Rech Cap Limited Liability (Trc) reported 1,141 shares. The Illinois-based Northern Corp has invested 0% in ADMA Biologics Inc (NASDAQ:ADMA).

The stock of Adma Biologics Incorporated (NASDAQ:ADMA) registered a decrease of 15.6% in short interest. ADMA’s total short interest was 57,900 shares in October as published by FINRA. Its down 15.6% from 68,600 shares, reported previously. With 21,000 shares average volume, it will take short sellers 3 days to cover their ADMA’s short positions. The short interest to Adma Biologics Incorporated’s float is 1.77%.

About 52,809 shares traded or 87.65% up from the average. ADMA Biologics Inc (NASDAQ:ADMA) has declined 37.56% since October 12, 2016 and is downtrending. It has underperformed by 54.26% the S&P500.

ADMA Biologics, Inc. is a late-stage biopharmaceutical firm that develops, makes and intends to market specialty plasma biologics for the treatment and prevention of infectious diseases. The company has market cap of $80.27 million. The Firm is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. It currently has negative earnings. The Company’s divisions include Plasma Collection Centers, which includes its activities in Georgia; Research and Development, which includes its plasma development activities in New Jersey, and Corporate.

ADMA Biologics Inc (NASDAQ:ADMA) Ratings Coverage

Among 2 analysts covering ADMA Biologics (NASDAQ:ADMA), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. ADMA Biologics had 7 analyst reports since September 9, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, June 7 by Maxim Group. The company was maintained on Thursday, September 17 by Maxim Group. The firm earned “Market Perform” rating on Monday, August 1 by Raymond James. The rating was downgraded by Maxim Group on Monday, August 1 to “Hold”. The rating was maintained by Maxim Group with “Buy” on Wednesday, June 28. Raymond James initiated the shares of ADMA in report on Wednesday, September 9 with “Strong Buy” rating. The company was upgraded on Monday, January 23 by Maxim Group.

More notable recent ADMA Biologics Inc (NASDAQ:ADMA) news were published by: Globenewswire.com which released: “ADMA Biologics Receives Complete Response Letter from FDA for Pending …” on July 29, 2016, also Seekingalpha.com with their article: “ADMA Bio set for growth after acquisition of Biotest assets, relaunch of …” published on June 27, 2017, Globenewswire.com published: “Marathon Asset Management and ADMA Biologics Complete $30 Million Debt Refinancing” on October 11, 2017. More interesting news about ADMA Biologics Inc (NASDAQ:ADMA) were released by: Seekingalpha.com and their article: “ADMA Biologics Follows Up On RI-002” published on July 26, 2017 as well as Seekingalpha.com‘s news article titled: “ADMA Biologics Down After FDA Setback, But Approval For RI-002 Almost Certain” with publication date: August 02, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.